HIV Infections Clinical Trial
Official title:
A Randomized Controlled Trial of a Mindfulness-Based Stress Reduction Intervention for Men Living With HIV
This study will examine the effectiveness of Mindfulness-Based Stress Reduction (MBSR) in
helping men living with HIV cope with negative emotions and stresses in their life. MBSR is
an approach to reducing stress for patients with chronic medical conditions. It involves
systematic training in mindfulness meditation practices to increase quality of life and to
reduce general stress, anxiety, depression or pain. The effectiveness of MBSR will be
evaluated by looking at changes in participants' experience of stress, anxiety associated
with pain management and psychosocial functioning before and after they receive the MBSR
compared with participants who do not receive the MBSR treatment.
In order to participate, individuals must be: male, living with HIV, age 18-70 years, live
within one hour of participating centre, and have a good understanding of the English
language. Questionnaires will be completed before individuals begin the program, at the end
of the intensive phase (8 weeks) and at 6 months after the start of the group program. The
primary program evaluation outcome will be a reduction in stress; secondary evaluation
outcomes will include the improvements in the physical and emotional experience of pain as
well as general psychosocial functioning and self-esteem.
In most health care settings, psychosocial interventions that target stress and distress
states that are integrated into routine HIV care will need to serve a large number of
patients. Due to their time- and cost- efficiency, group approaches are being used
increasingly in medical settings to address this need. One approach that has been used
successfully in cancer and other chronic diseases is mindfulness-based stress reduction
(MBSR), an 8-week manualized treatment program that provides mood management techniques
based on training in mindfulness, a metacognitive skill. A recent randomized controlled
trial in cancer demonstrated that this brief intervention significantly reduced anxiety and
depression symptoms and that these gains were maintained at a six-month follow-up. Similar
results have been obtained in a heterogeneous sample of medical patients. Although research
in this area is in its infancy, it does appear that MBSR may be effective in the management
of anxiety and mood symptoms that are common across various medical conditions and thus may
be a good treatment option in men living with HIV.
Preliminary evidence, gathered from a pilot assessment of an MBSR program for HIV positive
men, demonstrated significant pre- to post-intervention reductions in anxiety and
depression, as well as overall mood disturbance scores on standardized measures, and thus,
MBSR has promise in this population. A randomized controlled trial is clearly needed however
before can be recommended as a psychosocial treatment for men with HIV. It is predicted that
MBSR will be effective in mitigating anxiety and depressive symptoms, as well as HIV-related
distress, among HIV patients (Hypothesis #1).
MBSR appears to be particularly well suited for anxiety- and depression- spectrum symptoms
because it targets cognitive processes that contribute to and maintains them. Current
cognitive models emphasize the central role of worry and rumination in the onset and
maintenance of anxiety and depression, respectively. Worry can perpetuate an upward spiral
of increased emotional arousal and intrusive thoughts heightening anxiety symptoms.
Similarly, rumination can escalate a spiraling cycle of dysphoric affect and associated
negative thinking that can lead eventually to a major depressive episode. (MBSR utilizes
training in attention regulation that is thought to provide patients with a skill that
enables them to disengage from patterns of worry and rumination that otherwise would
perpetuate negative affect. Consistent with this prediction, Dr. Bishop (co-investigator)
has found evidence from a recently completed pilot study that mindfulness training results
in decreased frequency of worry and rumination. Although preliminary, MBSR may be associated
with decreases in both worry and rumination (Hypothesis #2) and that, consistent with
current cognitive models, decreases in worry and rumination would moderate the reductions in
anxiety and depression, respectively (Hypothesis #3).
We are also interested in whether this approach is effective for the management of pain,
which is prevalent in this population. There is substantial evidence that anxiety, and
particularly pain-related fear, can heighten the perception of the intensity and
unpleasantness of pain and that anxiety management can lessen pain. Since we anticipate that
MBSR will reduce anxiety in this study, we would further expect that it would also reduce
the subjective experience of pain (Hypothesis #4). There is some evidence from an
uncontrolled trial suggesting that MBSR may be highly effective for managing chronic pain.
If MBSR can be used to effectively mitigate pain, then this too would have a recursive
effect on mood. Pain in medical populations is a significant factor in emotional distress
and psychiatric morbidity.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |